Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 3/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.34 |
| ▸ | CA12 | O43570 | 2/20 | 0.34 |
| ▸ | CA1 | P00915 | 2/20 | 0.34 |
| ▸ | CA2 | P00918 | 2/20 | 0.34 |
| ▸ | MMP2 | P08253 | 2/20 | 0.34 |
| ▸ | CA9 | Q16790 | 2/20 | 0.34 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.33 |
| ▸ | DHODH | Q02127 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10622455 | 0.81 | EPHX1 (0.40) | EPHX1ATMKMT2AEPHX2CA12 | |
| SCHEMBL10885190 | 0.79 | SHBG (0.38) | TSHREPHX1ATMEPHX2ALDH1A1 | |
| SCHEMBL8444779 | 0.78 | TSHR (0.44) | TSHREPHX1LMNAMAPK1MEN1 | |
| SCHEMBL8674655 | 0.78 | TSHR (0.44) | TSHREPHX1LMNAMAPK1MEN1 | |
| SCHEMBL1055586 | 0.78 | TSHR (0.50) | TSHREPHX1LMNAMAPK1ATM | |
| SCHEMBL1051503 | 0.78 | TSHR (0.50) | TSHREPHX1LMNAMAPK1ATM | |
| SCHEMBL11170830 | 0.78 | TSHR (0.50) | TSHREPHX1LMNAMAPK1ATM | |
| SCHEMBL873507 | 0.78 | TSHR (0.50) | TSHREPHX1LMNAMAPK1ATM | |
| SCHEMBL9609345 | 0.78 | TSHR (0.44) | TSHREPHX1LMNAMAPK1MEN1 | |
| SCHEMBL10656599 | 0.77 | TSHR (0.32) | TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113056457-A | 4- ((1R,3S) -6-chloro-3-phenyl-2, 3-dihydro-1H-inden-1-yl) -1,2, 2-trimethylpiperazine and 4- ((1R,3S) -6-chloro-3- (phenyl-d)5) -2, 3-dihydro-1H-inden-1-yl) -2, 2-dimethyl-1- (methyl-d3) Prodrugs of piperazine | H.隆德贝克有限公司 | 2021-06-29 | — | — | CN | disclosed |
| CN-109988186-A | Beta-lactamase inhibitor | 维纳拓尔斯制药公司 | 2019-07-09 | — | — | CN | disclosed |
| CN-106687465-B | β -lactamase inhibitor | 维纳拓尔斯制药公司 | 2019-04-16 | — | — | CN | disclosed |
| CN-106687465-A | Beta-lactamase inhibitors | 维纳拓尔斯制药公司 | 2017-05-17 | — | — | CN | disclosed |
| US-20110118229-A1 | 2-ARYLMETHYLAZETIDINE-CARBAPENEM-3-CARBOXYLIC ACID ESTER DERIVATIVE OR ITS SALT, PROCESS FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | KUKJE PHARM. IND. CO., LTD. (KR) | 2011-05-19 | — | — | US | disclosed |
| EP-2212325-A2 | 2-ARYLMETHYLAZETIDINE-CARBAPENEM-3-CARBOXYLIC ACID ESTER DERIVATIVE OR ITS SALT, PROCESS FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | Kukje Pharm. Ind. Co., Ltd. (KR) | 2010-08-04 | — | — | EP | disclosed |
| WO-2009066917-A2 | 2-ARYLMETHYLAZETIDINE-CARBAPENEM-3-CARBOXYLIC ACID ESTER DERIVATIVE OR ITS SALT, PROCESS FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | KUKJE PHARM. IND. CO., LTD. (KR) | 2009-05-28 | — | — | WO | disclosed |
| EP-0808315-B1 | CARBAPENEM-3-CARBOXYLIC ACID ESTER DERIVATIVES | WYETH LEDERLE JAPAN LTD (JP) | 2001-04-04 | — | — | EP | disclosed |
| US-5886172-A | ORAL PRODRUG READILY ABSORPED IN THE DIGESTIVE TRACT AND HYDROLYZED; BIOAVAILABIITY; STRONG ANTIBACTERIAL ACTIVITY ESPECIALLY AGAINST STAPHYLOCOCCUS; STREPTOCOCCUS, KLEBSIELLA AND PROTEUS | LEDERLE (JAPAN) LTD. (JP) | 1999-03-23 | — | — | US | disclosed |
| EP-0808315-A1 | CARBAPENEM-3-CARBOXYLIC ACID ESTER DERIVATIVES | LEDERLE (JAPAN), Ltd. (JP) | 1997-11-26 | — | — | EP | disclosed |
| WO-1997021712-A1 | CARBAPENEM-3-CARBOXYLIC ACID ESTER DERIVATIVES | LEDERLE (JAPAN), LTD. (JP) | 1997-06-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110118229-A1 | 2-ARYLMETHYLAZETIDINE-CARBAPENEM-3-CARBOXYLIC ACID ESTER DERIVATIVE OR ITS SALT, PROCESS FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | CYP2C19, CYP2C9, SCN9A | TSHR 4168/4885EPHX1 3676/4885LMNA 1267/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.